Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jul 31 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received marketing approval from COFEPRIS in Mexico for Mamitra™, a Trastuzumab biosimilar used to treat various cancers. The approval allows Zydus to expand its biosimilar portfolio into new markets, providing access to affordable therapies for cancer patients. Dr. Sharvil Patel, Managing Director, emphasized the company's commitment to addressing unmet healthcare needs globally through innovation. Zydus has previously launched this biosimilar in India under the brand name Vivitra, treating a significant number of patients since its introduction.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 31, 2024, titled "Zydus receives approval from COFEPRIS of Mexico to market Mamitra (Trastuzumab biosimilar) to treat various cancers".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases